Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by JohnEnglishon Mar 18, 2015 8:12am
61 Views
Post# 23532881

RE:Looks like funding may be in place already

RE:Looks like funding may be in place alreadyI think that's a good question. They had a similiar agreement with a Latin American partner but they put out a press release last April announcing that LOI had been cancelled. If the same happened with the Chinese partner I'd imagine they'd have to do the same so I think it's fair to assume that it's still in place.

This may be part of the reason why they're running the additional validation studies prior to commencing Phase 2 trials. I would imagine that the agreement they have with the Chinese company is not just a "start Phase 2 and we'll cover all the costs" type deal. I assume there would be all sorts of prerequisites prior to getting funding. Since Phase 1 didn't go exactly as planned, these validation studies may be part of the process showing that the drug is still effective so that they can get access to all or part of that funding to start Phase 2 trials.
Bullboard Posts